Quarterly report pursuant to Section 13 or 15(d)

Non-controlling Interest (Details)

v3.21.1
Non-controlling Interest (Details) - USD ($)
3 Months Ended 28 Months Ended
Sep. 05, 2018
Mar. 31, 2021
Mar. 31, 2020
Dec. 31, 2020
Noncontrolling Interest        
Related Party Transaction, Expenses from Transactions with Related Party       $ 328,000
Research and Development Expense   $ 1,118,000 $ 1,635,000  
Net Income (Loss) Attributable to Noncontrolling Interest   $ (1,000) (26,000)  
SYN Biomics [Member]        
Noncontrolling Interest        
Equity interest by parent   83.00%    
Related Party Transaction, Expenses from Transactions with Related Party   $ 0    
Research and Development Expense     67,000  
Accumulated net loss attributable to the non-controlling interest   $ 2,800,000 $ 2,900,000  
Cedarssinai Medical Center [Member]        
Noncontrolling Interest        
Number Of Common Stock To Be Issued 50,000      
Fair Value Of Shares Issued $ 285,000      
Cedarssinai Medical Center [Member] | SYN Biomics [Member]        
Noncontrolling Interest        
Additional Number Of Common Stock To Be Issued 2,420,000      
Number Of Common Stock To Be Held By Related Party 7,480,000      
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners 17.00%